Email updates

Keep up to date with the latest news and content from BMC Nephrology and BioMed Central.

Open Access Highly Accessed Research article

Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry

Víctor Martínez1, Jordi Comas2, Emma Arcos2, Joan Manel Díaz3, Salomé Muray1, Juan Cabezuelo1, José Ballarín2, Elisabet Ars4 and Roser Torra5*

Author affiliations

1 Nephrology Department, Hospital Reina Sofia, Murcia, Spain

2 Catalan Renal Registry, Catalan Transplant Organization, Health Department, Generalitat of Catalonia, Barcelona, Spain

3 Nephrology Department, Fundacio Puigvert, IIB Sant Pau, Univeristat Autónoma de Barcelona, Barcelona, Spain

4 Molecular Biology Laboratory, Fundacio Puigvert, IIB Sant Pau, Univeristat Autónoma de Barcelona, Barcelona, Spain

5 Inherited Renal Diseases, Nephrology Department, Fundacio Puigvert, IIB Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain

For all author emails, please log on.

Citation and License

BMC Nephrology 2013, 14:186  doi:10.1186/1471-2369-14-186

Published: 5 September 2013

Abstract

Background

Some 7-10% of patients on replacement renal therapy (RRT) are receiving it because of autosomal dominant polycystic kidney disease (ADPKD). The age at initiation of RRT is expected to increase over time.

Methods

Clinical data of 1,586 patients (7.9%) with ADPKD and 18,447 (92.1%) patients with other nephropathies were analysed from 1984 through 2009 (1984–1991, 1992–1999 and 2000–2009).

Results

The age at initiation of RRT remained stable over the three periods in the ADPKD group (56.7 ± 10.9 (mean ± SD) vs 57.5 ± 12.1 vs 57.8 ± 13.3 years), whereas it increased significantly in the non-ADPKD group (from 54.8 ± 16.8 to 63.9 ± 16.3 years, p < 0.001). The ratio of males to females was higher for non-ADPKD than for ADPKD patients (1.6–1.8 vs 1.1–1.2). The prevalence of diabetes was significantly lower in the ADPKD group (6.76% vs 11.89%, p < 0.001), as were most of the co-morbidities studied, with the exception of hypertension. The survival rate of the ADPKD patients on RRT was higher than that of the non-ADPKD patients (p < 0.001).

Conclusions

Over time neither changes in age nor alterations in male to female ratio have occurred among ADPKD patients who have started RRT, probably because of the impact of unmodifiable genetic factors in the absence of a specific treatment.

Keywords:
Autosomal dominant polycystic kidney disease; Renal replacement therapy; Survival; Co-morbidities; ADPKD